Evaluation of inhibitory actions of antidepressants on muscarinic receptors assessed by a binding assay in the mouse cerebral neocortex

J Pharmacol Sci. 2024 Dec;156(4):214-217. doi: 10.1016/j.jphs.2024.09.001. Epub 2024 Sep 11.

Abstract

We investigated the inhibitory effects of 32 antidepressants on [3H]N-methylscopolamine ([3H]NMS)-specific binding in the mouse cerebral neocortex to determine which antidepressants should be recommended for patients with Alzheimer's disease (AD). Of those tested, nine antidepressants (10-4 M) exhibited less inhibitory effect on [3H]NMS-specific binding (<35%): tianeptine (a tricyclic); trazodone (a serotonin 5-HT2A blocker); sulpiride (a dopamine D2 blocker); fluvoxamine (a selective serotonin reuptake inhibitor (RI)); milnacipran, levomilnacipran, venlafaxine, and desvenlafaxine (serotonin and noradrenaline RIs); and bupropion (a noradrenaline and dopamine RI). Therefore, these antidepressants show little anticholinergic effect in the brain and are recommended for use in patients with AD.

Keywords: Anticholinergic action; Antidepressants; Mouse cerebral neocortex.

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / metabolism
  • Animals
  • Antidepressive Agents* / pharmacology
  • Male
  • Mice
  • Neocortex* / drug effects
  • Neocortex* / metabolism
  • Receptors, Muscarinic* / metabolism
  • Scopolamine / pharmacology

Substances

  • Antidepressive Agents
  • Receptors, Muscarinic
  • Scopolamine